Nitroso–Redox Balance in the Cardiovascular System
In this issue of the Journal, Taylor and colleagues report the results of the African-American Heart Failure Trial (A-HeFT), a double-blind, randomized trial that evaluated the effect of the addition of isosorbide dinitrate and hydralazine to the best conventional therapy in patients with symptomati...
Gespeichert in:
| Veröffentlicht in: | The New England journal of medicine 2004-11, Vol.351 (20), p.2112-2114 |
|---|---|
| 1. Verfasser: | |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2114 |
|---|---|
| container_issue | 20 |
| container_start_page | 2112 |
| container_title | The New England journal of medicine |
| container_volume | 351 |
| creator | Hare, Joshua M |
| description | In this issue of the
Journal,
Taylor and colleagues report the results of the African-American Heart Failure Trial (A-HeFT), a double-blind, randomized trial that evaluated the effect of the addition of isosorbide dinitrate and hydralazine to the best conventional therapy in patients with symptomatic congestive heart failure who identified themselves as black.
1
The results with the combination therapy were markedly positive, meeting the composite end point of the trial, which included death from any cause, a first hospitalization for heart failure, and quality-of-life measures. In addition, there was an impressive reduction in the rate of death from any cause of . . . |
| doi_str_mv | 10.1056/NEJMe048269 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_67062468</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>67062468</sourcerecordid><originalsourceid>FETCH-LOGICAL-c404t-776951f0ae71e6a338baa19240e0712f3e5902dffdf82866afb5f6a79dc0a383</originalsourceid><addsrcrecordid>eNpt0MtKw0AUBuBBFFurK_cSENxI9EzmlllqqTdqBe0-TJMzmJJp6kwiduc7-IY-iSkt6MLZnM3Hf878hBxTuKAg5OVk9PCIwNNE6h3Sp4KxmHOQu6QPkKQxV5r1yEEIc-ge5Xqf9KjoVCpYn_BJ2fg61N-fX89Y1B_RtanMIseoXETNK0ZD44uyfjchbyvjo5dVaNAdkj1rqoBH2zkg05vRdHgXj59u74dX4zjnwJtYKakFtWBQUZSm2zgzhuqEA4KiiWUoNCSFtYVNk1RKY2fCSqN0kYNhKRuQs03s0tdvLYYmc2XIseoOxLoNmVQgEy7X8HwD8-4rwaPNlr50xq8yCtm6o-xPR50-2ca2M4fFr92W0oHTDXAuZAucu39jfgAoR2wr</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>67062468</pqid></control><display><type>article</type><title>Nitroso–Redox Balance in the Cardiovascular System</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>ProQuest Central UK/Ireland</source><source>New England Journal of Medicine</source><creator>Hare, Joshua M</creator><creatorcontrib>Hare, Joshua M</creatorcontrib><description>In this issue of the
Journal,
Taylor and colleagues report the results of the African-American Heart Failure Trial (A-HeFT), a double-blind, randomized trial that evaluated the effect of the addition of isosorbide dinitrate and hydralazine to the best conventional therapy in patients with symptomatic congestive heart failure who identified themselves as black.
1
The results with the combination therapy were markedly positive, meeting the composite end point of the trial, which included death from any cause, a first hospitalization for heart failure, and quality-of-life measures. In addition, there was an impressive reduction in the rate of death from any cause of . . .</description><identifier>ISSN: 0028-4793</identifier><identifier>EISSN: 1533-4406</identifier><identifier>DOI: 10.1056/NEJMe048269</identifier><identifier>PMID: 15533853</identifier><language>eng</language><publisher>United States: Massachusetts Medical Society</publisher><subject>African Continental Ancestry Group ; Cardiovascular System - metabolism ; Drug Combinations ; Heart Failure - drug therapy ; Heart Failure - ethnology ; Heart Failure - metabolism ; Humans ; Hydralazine - therapeutic use ; Isosorbide Dinitrate - pharmacology ; Isosorbide Dinitrate - therapeutic use ; Nitric Oxide - biosynthesis ; Nitric Oxide Donors - pharmacology ; Nitric Oxide Donors - therapeutic use ; Nitric Oxide Synthase - metabolism ; Oxidation-Reduction ; Signal Transduction ; Superoxides - metabolism ; Vasodilator Agents - therapeutic use</subject><ispartof>The New England journal of medicine, 2004-11, Vol.351 (20), p.2112-2114</ispartof><rights>Copyright © 2004 Massachusetts Medical Society. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c404t-776951f0ae71e6a338baa19240e0712f3e5902dffdf82866afb5f6a79dc0a383</citedby><cites>FETCH-LOGICAL-c404t-776951f0ae71e6a338baa19240e0712f3e5902dffdf82866afb5f6a79dc0a383</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.nejm.org/doi/pdf/10.1056/NEJMe048269$$EPDF$$P50$$Gmms$$H</linktopdf><linktohtml>$$Uhttps://www.nejm.org/doi/full/10.1056/NEJMe048269$$EHTML$$P50$$Gmms$$H</linktohtml><link.rule.ids>314,780,784,2757,2758,26102,27923,27924,52381,54063,64386</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15533853$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hare, Joshua M</creatorcontrib><title>Nitroso–Redox Balance in the Cardiovascular System</title><title>The New England journal of medicine</title><addtitle>N Engl J Med</addtitle><description>In this issue of the
Journal,
Taylor and colleagues report the results of the African-American Heart Failure Trial (A-HeFT), a double-blind, randomized trial that evaluated the effect of the addition of isosorbide dinitrate and hydralazine to the best conventional therapy in patients with symptomatic congestive heart failure who identified themselves as black.
1
The results with the combination therapy were markedly positive, meeting the composite end point of the trial, which included death from any cause, a first hospitalization for heart failure, and quality-of-life measures. In addition, there was an impressive reduction in the rate of death from any cause of . . .</description><subject>African Continental Ancestry Group</subject><subject>Cardiovascular System - metabolism</subject><subject>Drug Combinations</subject><subject>Heart Failure - drug therapy</subject><subject>Heart Failure - ethnology</subject><subject>Heart Failure - metabolism</subject><subject>Humans</subject><subject>Hydralazine - therapeutic use</subject><subject>Isosorbide Dinitrate - pharmacology</subject><subject>Isosorbide Dinitrate - therapeutic use</subject><subject>Nitric Oxide - biosynthesis</subject><subject>Nitric Oxide Donors - pharmacology</subject><subject>Nitric Oxide Donors - therapeutic use</subject><subject>Nitric Oxide Synthase - metabolism</subject><subject>Oxidation-Reduction</subject><subject>Signal Transduction</subject><subject>Superoxides - metabolism</subject><subject>Vasodilator Agents - therapeutic use</subject><issn>0028-4793</issn><issn>1533-4406</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpt0MtKw0AUBuBBFFurK_cSENxI9EzmlllqqTdqBe0-TJMzmJJp6kwiduc7-IY-iSkt6MLZnM3Hf878hBxTuKAg5OVk9PCIwNNE6h3Sp4KxmHOQu6QPkKQxV5r1yEEIc-ge5Xqf9KjoVCpYn_BJ2fg61N-fX89Y1B_RtanMIseoXETNK0ZD44uyfjchbyvjo5dVaNAdkj1rqoBH2zkg05vRdHgXj59u74dX4zjnwJtYKakFtWBQUZSm2zgzhuqEA4KiiWUoNCSFtYVNk1RKY2fCSqN0kYNhKRuQs03s0tdvLYYmc2XIseoOxLoNmVQgEy7X8HwD8-4rwaPNlr50xq8yCtm6o-xPR50-2ca2M4fFr92W0oHTDXAuZAucu39jfgAoR2wr</recordid><startdate>20041111</startdate><enddate>20041111</enddate><creator>Hare, Joshua M</creator><general>Massachusetts Medical Society</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20041111</creationdate><title>Nitroso–Redox Balance in the Cardiovascular System</title><author>Hare, Joshua M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c404t-776951f0ae71e6a338baa19240e0712f3e5902dffdf82866afb5f6a79dc0a383</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>African Continental Ancestry Group</topic><topic>Cardiovascular System - metabolism</topic><topic>Drug Combinations</topic><topic>Heart Failure - drug therapy</topic><topic>Heart Failure - ethnology</topic><topic>Heart Failure - metabolism</topic><topic>Humans</topic><topic>Hydralazine - therapeutic use</topic><topic>Isosorbide Dinitrate - pharmacology</topic><topic>Isosorbide Dinitrate - therapeutic use</topic><topic>Nitric Oxide - biosynthesis</topic><topic>Nitric Oxide Donors - pharmacology</topic><topic>Nitric Oxide Donors - therapeutic use</topic><topic>Nitric Oxide Synthase - metabolism</topic><topic>Oxidation-Reduction</topic><topic>Signal Transduction</topic><topic>Superoxides - metabolism</topic><topic>Vasodilator Agents - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hare, Joshua M</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>The New England journal of medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hare, Joshua M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Nitroso–Redox Balance in the Cardiovascular System</atitle><jtitle>The New England journal of medicine</jtitle><addtitle>N Engl J Med</addtitle><date>2004-11-11</date><risdate>2004</risdate><volume>351</volume><issue>20</issue><spage>2112</spage><epage>2114</epage><pages>2112-2114</pages><issn>0028-4793</issn><eissn>1533-4406</eissn><abstract>In this issue of the
Journal,
Taylor and colleagues report the results of the African-American Heart Failure Trial (A-HeFT), a double-blind, randomized trial that evaluated the effect of the addition of isosorbide dinitrate and hydralazine to the best conventional therapy in patients with symptomatic congestive heart failure who identified themselves as black.
1
The results with the combination therapy were markedly positive, meeting the composite end point of the trial, which included death from any cause, a first hospitalization for heart failure, and quality-of-life measures. In addition, there was an impressive reduction in the rate of death from any cause of . . .</abstract><cop>United States</cop><pub>Massachusetts Medical Society</pub><pmid>15533853</pmid><doi>10.1056/NEJMe048269</doi><tpages>3</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0028-4793 |
| ispartof | The New England journal of medicine, 2004-11, Vol.351 (20), p.2112-2114 |
| issn | 0028-4793 1533-4406 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_67062468 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; ProQuest Central UK/Ireland; New England Journal of Medicine |
| subjects | African Continental Ancestry Group Cardiovascular System - metabolism Drug Combinations Heart Failure - drug therapy Heart Failure - ethnology Heart Failure - metabolism Humans Hydralazine - therapeutic use Isosorbide Dinitrate - pharmacology Isosorbide Dinitrate - therapeutic use Nitric Oxide - biosynthesis Nitric Oxide Donors - pharmacology Nitric Oxide Donors - therapeutic use Nitric Oxide Synthase - metabolism Oxidation-Reduction Signal Transduction Superoxides - metabolism Vasodilator Agents - therapeutic use |
| title | Nitroso–Redox Balance in the Cardiovascular System |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-12T10%3A17%3A35IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Nitroso%E2%80%93Redox%20Balance%20in%20the%20Cardiovascular%20System&rft.jtitle=The%20New%20England%20journal%20of%20medicine&rft.au=Hare,%20Joshua%20M&rft.date=2004-11-11&rft.volume=351&rft.issue=20&rft.spage=2112&rft.epage=2114&rft.pages=2112-2114&rft.issn=0028-4793&rft.eissn=1533-4406&rft_id=info:doi/10.1056/NEJMe048269&rft_dat=%3Cproquest_cross%3E67062468%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=67062468&rft_id=info:pmid/15533853&rfr_iscdi=true |